Metformin HCL ER
ID: SPE2D2-23-D-0008Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/f29923ee78c24d5ca99ae10b5174bcc6/view
Timeline
    Description

    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is procuring Metformin HCL ER. Metformin HCL ER is a drug used to treat type 2 diabetes. This procurement is being conducted by DLA TROOP SUPPORT. For more information, contact Christopher Newman at christopher.newman@dla.mil or 2157372905.

    Files
    Title
    Posted
    Metformin Award SPE2D223D0008 Final BILATERLLY signed.pdf
    Lifecycle
    Title
    Type
    Metformin HCL ER
    Currently viewing
    Special Notice
    Similar Opportunities
    Metformin HCL
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    Tolterodine Tartrate ER
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is seeking Tolterodine Tartrate ER. Tolterodine Tartrate ER is a drug used for the treatment of overactive bladder. The procurement will be fulfilled by DLA Troop Support in Philadelphia, PA, USA. For more information, contact Catherine Gilbert at catherine.gilbert@dla.mil or 2157374778.
    Repaglinide
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Repaglinide Tablets. The contract will establish a national supply source for the purchase of Repaglinide 0.5MG, 1MG, and 2MG in 100 count bottles. This acquisition will be unrestricted and fully competitive. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items listed in the schedule will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. Interested parties should contact Phyllis Daraio for any questions/comments. The projected solicitation date is September 2020.
    Duloxetine HCL DR
    Active
    Dept Of Defense
    Presolicitation notice for Duloxetine HCL DR. The service/item being procured is typically used for medical, dental, and veterinary equipment and supplies. The place of performance is in Philadelphia, PA, USA at DLA Troop Support, 700 Robbins Avenue, 19111. The primary contact for this procurement is Joan Grace, who can be reached at JoanMarie.Grace@dla.mil or 215-737-2663.
    Potassium Chloride Extended Release Tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is soliciting offers for Potassium Chloride Extended Release Tablets under solicitation number SPE2D2-24-R-0013. This procurement aims to acquire pharmaceutical products in various quantities, ensuring that suppliers meet federal standards for quality and compliance. Potassium Chloride is a critical medication used for treating and preventing potassium deficiency, highlighting the importance of reliable supply in healthcare settings. Interested vendors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) by the deadline of October 10, 2024. For further inquiries, potential bidders can contact Ryan Guarnere at ryan.guarnere@dla.mil or Jason Wray at jason.wray@dla.mil.
    Trazodone HCL
    Active
    Dept Of Defense
    Solicitation DEPT OF DEFENSE is procuring Trazodone HCL, a drug used for treating depression and anxiety. The procurement will take place at DLA Troop Support in Philadelphia, PA (zip code: 19111), USA. For more information, contact Christopher Newman at christopher.newman@dla.mil or 215-737-2905.
    Sertraline HCL National Contract
    Active
    Dept Of Defense
    Presolicitation notice for a national contract for Sertraline HCL. Sertraline HCL is a medical/dental/veterinary equipment/supply used for the treatment of depression, panic attacks, obsessive-compulsive disorder, post-traumatic stress disorder, and social anxiety disorder. Contact Danielle Delaney at Danielle.Delaney@dla.mil or 215-737-2998 for more information.
    Pantoprazole DR Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
    Valsartan
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used to treat high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The solicitation will be posted on the DLA Bid Board System and beta.SAM.gov, with a projected solicitation date in June 2021. Interested parties should contact Christopher Newman for more information.
    Telmisartan Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Telmisartan Tablets. Telmisartan Tablets are pharmaceutical preparations used to treat high blood pressure and reduce the risk of heart attack, stroke, and kidney problems in certain patients. The tablets will be available in 20MG, 40MG, and 80MG strengths, packaged in 30 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. The contract aims to establish a national supply source to provide Telmisartan Tablets to Department of Defense, Bureau of Prisons, Indian Health Service, and Department of Veterans Affairs customers through the DLA and VA prime vendor programs. Interested parties can contact Courtney Hunter-Stangler at (215) 737-6845 or Courtney.Hunter-Stangler@dla.mil for any questions/comments. The solicitation is projected to be issued in August of 2024.